Compare Cipla with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AJANTA PHARMA - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AJANTA PHARMA CIPLA/
AJANTA PHARMA
 
P/E (TTM) x 29.3 24.6 118.8% View Chart
P/BV x 4.1 6.8 60.4% View Chart
Dividend Yield % 0.5 0.5 96.0%  

Financials

 CIPLA   AJANTA PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-20
AJANTA PHARMA
Mar-19
CIPLA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs5861,422 41.2%   
Low Rs357898 39.8%   
Sales per share (Unadj.) Rs207.0233.5 88.7%  
Earnings per share (Unadj.) Rs18.644.0 42.3%  
Cash flow per share (Unadj.) Rs33.252.2 63.6%  
Dividends per share (Unadj.) Rs4.009.00 44.4%  
Dividend yield (eoy) %0.80.8 109.4%  
Book value per share (Unadj.) Rs195.5255.1 76.6%  
Shares outstanding (eoy) m806.3588.02 916.1%   
Bonus/Rights/Conversions ESOSBB-  
Price / Sales ratio x2.35.0 45.8%   
Avg P/E ratio x25.326.4 96.0%  
P/CF ratio (eoy) x14.222.2 63.9%  
Price / Book Value ratio x2.44.5 53.0%  
Dividend payout %21.520.5 105.1%   
Avg Mkt Cap Rs m379,912102,081 372.2%   
No. of employees `00025.86.8 380.1%   
Total wages/salary Rs m30,2704,307 702.8%   
Avg. sales/employee Rs Th6,459.63,022.6 213.7%   
Avg. wages/employee Rs Th1,171.2633.4 184.9%   
Avg. net profit/employee Rs Th580.2569.1 102.0%   
INCOME DATA
Net Sales Rs m166,94920,554 812.3%  
Other income Rs m3,442211 1,632.8%   
Total revenues Rs m170,39120,765 820.6%   
Gross profit Rs m32,0605,664 566.0%  
Depreciation Rs m11,747721 1,629.6%   
Interest Rs m1,97412 17,013.8%   
Profit before tax Rs m21,7825,143 423.5%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,3121,273 495.8%   
Profit after tax Rs m14,9953,870 387.5%  
Gross profit margin %19.227.6 69.7%  
Effective tax rate %29.024.8 117.1%   
Net profit margin %9.018.8 47.7%  
BALANCE SHEET DATA
Current assets Rs m117,03811,812 990.8%   
Current liabilities Rs m43,9313,776 1,163.3%   
Net working cap to sales %43.839.1 112.0%  
Current ratio x2.73.1 85.2%  
Inventory Days Days9677 123.7%  
Debtors Days Days8582 104.3%  
Net fixed assets Rs m107,42414,398 746.1%   
Share capital Rs m1,613175 919.3%   
"Free" reserves Rs m156,01822,277 700.4%   
Net worth Rs m157,63022,452 702.1%   
Long term debt Rs m23,6937 358,981.8%   
Total assets Rs m236,62626,962 877.6%  
Interest coverage x12.0444.3 2.7%   
Debt to equity ratio x0.20 51,131.7%  
Sales to assets ratio x0.70.8 92.6%   
Return on assets %7.214.4 49.8%  
Return on equity %9.517.2 55.2%  
Return on capital %12.823.0 55.9%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03610,682 524.6%   
Fx outflow Rs m6,7642,102 321.8%   
Net fx Rs m49,2728,580 574.3%   
CASH FLOW
From Operations Rs m30,6853,748 818.7%  
From Investments Rs m1,040-2,228 -46.7%  
From Financial Activity Rs m-29,488-1,475 1,999.7%  
Net Cashflow Rs m2,34045 5,177.4%  

Share Holding

Indian Promoters % 16.0 73.8 21.7%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 1.6 787.1%  
FIIs % 23.7 7.6 311.8%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 17.0 154.1%  
Shareholders   161,166 20,968 768.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)

Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Intraday Trading for a Living(Fast Profits Daily)

Feb 15, 2021

In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.

Penny Stock Master Series: The Quest for 10X Profits in 10 Years(Profit Hunter)

Feb 12, 2021

This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 25, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS